Up­dat­ed: Con­tro­ver­sial opi­oid Zo­hy­dro ER pulled from the mar­ket

As the Bel­gian phar­ma UCB re­cent­ly inked a $1.9 bil­lion deal to buy out Zo­genix and its top drug for epilep­sy, the com­pa­ny’s for­mer con­tro­ver­sial opi­oid has now been pulled from the mar­ket, ac­cord­ing to a Fed­er­al Reg­is­ter fil­ing by the FDA on Tues­day.

Hy­drocodone-based Zo­hy­dro ER — which ini­tial­ly won FDA ap­proval in 2013 de­spite not hav­ing abuse-de­ter­rent prop­er­ties and de­spite an 11-2 ad­comm vote against ap­proval — is now one of 29 new drug ap­pli­ca­tions from mul­ti­ple spon­sors that have de­cid­ed to pull their drugs from the mar­ket for var­i­ous rea­sons, ac­cord­ing to the fil­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.